Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma

Gut

Volumn 60, Issue 5, 2011, Pages 695-701

  Tagaram, Hephzibah Rani S ^a   DiVittore, Nicole A ^a   Barth, Brian M ^a   Kaiser, James M ^a   Avella, Diego ^a   Kimchi, Eric T ^a   Jiang, Yixing ^a   Isom, Harriet C ^a   Kester, Mark ^a   Staveley O'Carroll, Kevin F ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CERAMIDE; LIPOCORTIN 5; NANOLIPOSOMAL C6 CERAMIDE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL LINE; CELL PROLIFERATION; CELL STRAIN SK HEP 1; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CERAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIPOSOMES; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953740653     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.216671     Document Type: Article

References (37)

1. Shariff MI, Cox IJ, Gomaa AI, et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009;3:353-67.
2. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31:461-76.
3. Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2010;26:189-95.
4. Lee JO, Kim DY, Lim JH, et al. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 2009;24:800-5.
5. Uhm JE, Park JO, Lee J, et al. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63:929-35.
6. Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J 2009;50:601-12.
7. Sotiropoulos GC, Malago M, Molmenti EP, et al. Impact of a living donor liver transplant program for hepatocellular carcinoma to the running local deceased donor liver transplant program. Dig Dis Sci 2010;55:872-3.
8. Chua TC, Liauw W, Saxena A, et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int 2009;30:166-74.
9. Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008;2:453-62.
10. Kolesnick RN, Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998;60:643-65.
11. Hannun YA, Obeid LM. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci 1995;20:73-7.
12. Dobrowsky RT, Jenkins GM, Hannun YA. Neurotrophins induce sphingomyelin hydrolysis. Modulation by co-expression of p75NTR with Trk receptors. J Biol Chem 1995;270:22135-42.
13. Shabbits JA, Mayer LD. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta 2003;1612:98-106. (Pubitemid 36555692)
14. Stover T, Kester M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther 2003;307:468-75. (Pubitemid 37310658)
15. Stover TC, Sharma A, Robertson GP, et al. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005;11:3465-74. (Pubitemid 40627901)
16. Tran MA, Smith CD, Kester M, et al. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 2008;14:3571-81.
17. Niwa S, Graf C, Bornancin F. Ceramide kinase deficiency impairs microendothelial cell angiogenesis in vitro. Microvasc Res 2009;77:389-93.
18. Zolnik BS, Stern ST, Kaiser JM, et al. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos 2008;36:1709-15.
19. Xiong YQ, Sun HC, Zhang W, et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009;15:4838-46.
20. Zhao XL, Du J, Zhang SW, et al. [A study on vasculogenic mimicry in hepatocellular carcinoma]. Chung Hua.Kan Tsang Ping Tsa Chih 2006;14:41-4.
21. Sun B, Zhang S, Zhang D, et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 2006;16:693-8.
22. Wang J, Lv XW, Shi JP, et al. Mechanisms involved in ceramide-induced cell cycle arrest in human hepatocarcinoma cells. World J Gastroenterol 2007;13:1129-34. (Pubitemid 46511019)
23. Liang J.Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45.
24. Li H, Junk P, Huwiler A, et al. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation 2002;106:2250-6. (Pubitemid 35222221)
25. Kornberg A, Kupper B, Tannapfel A, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 2010;36:275-80.
26. Lao OB, Weissman J, Perkins JD. Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation. Clin Transplant 2009;23:874-81.
27. Kerr SH, Kerr DJ. Novel treatments for hepatocellular cancer. Cancer Lett 2009;286:114-20.
28. Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008;49:413-40.
29. Heakal Y, Kester M. Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells. Mol Cancer Res 2009;7:724-34.
30. Basu S, Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene 1998;17:3277-85. (Pubitemid 29043980)
31. Bourbon NA, Sandirasegarane L, Kester M. Ceramide-induced inhibition of Akt is mediated through protein kinase C zeta: implications for growth arrest. J Biol Chem 2002;277:3286-92. (Pubitemid 34953194)
32. Fox TE, Houck KL, O'Neill SM, et al. Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J Biol Chem 2007;282:12450-7. (Pubitemid 47100622)
33. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4:604-16. (Pubitemid 39025055)
34. Mesri M, Morales-Ruiz M, Ackermann EJ, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001;158:1757-65. (Pubitemid 32422940)
35. Jayadev S, Liu B, Bielawska AE, et al. Role for ceramide in cell cycle arrest. J Biol Chem 1995;270:2047-52.
36. Colombaioni L, Frago LM, Varela-Nieto I, et al. Serum deprivation increases ceramide levels and induces apoptosis in undifferentiated HN9.10e cells. Neurochem Int 2002;40:327-36. (Pubitemid 34131607)
37. Ogretmen B, Pettus BJ, Rossi MJ, et al. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J Biol Chem 2002;277:12960-9. (Pubitemid 34952664)